Matt Kaeberlein, a longevity researcher and CEO of Optispan, had symptoms of low testosterone. He got his levels tested in his 50s and gradually began testosterone replacement therapy (TRT). He said ...

Federal officials may remove warnings on testosterone therapy drugs about heart and prostate risks, which could expand access ...

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase. Accessing Testosterone Replacement Therapy shouldn’t make you ...